Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiosurgery (SRS) for Spine Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Signed informed consent.~* Age greater than or equal to 18 years old.~* Prior histologically-proven, non-hematogenous malignancy (Specific exclusions are multiple myeloma and lymphoma).~* Radiographic evidence of one or two non-contiguous spinal metastases amenable to SRS.~* Metastatic disease must be symptomatic (causing either pain or neurologic symptoms).~* Maximum tumor size less than or equal to 5 cm.~* Zubrod performance status of less than or equal to 3.~* Life expectancy of greater than or equal to 3 months.~* Women/Men of childbearing potential must use effective contraception.~Exclusion Criteria:~* No prior radiation delivered to the involved area~* No evidence of spinal instability requiring urgent surgical intervention.~* No evidence of spinal cord compression requiring emergent surgical or radiotherapeutic intervention.~* No plans for concomitant antineoplastic therapy (including standard fractionated RT, chemotherapy, biologic, vaccine therapy, or surgery) while on this protocol except at disease progression.Concomitant is defined as within 3 days before or after radiosurgery.~* No pregnant or lactating women.~* No active systemic infection.~* No evidence of myelopathy or cauda equina syndrome on clinical evaluation

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1 (Type: ACTIVE_COMPARATOR): Low-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 14 Gy
- 2 (Type: ACTIVE_COMPARATOR): High-dose arm Single-fraction Stereotactic Radiosurgery (SRS) to 18Gy

Based on this trial design, predict the completion outcome and termination type (if applicable).